What does CELLSEARCH® Circulating Tumor Cell (CTC) Test cost?

FDA-cleared liquid biopsy platform for metastatic cancer monitoring—pricing driven by test volume, professional interpretation, and payer coverage variations

Current market pricing for the CELLSEARCH® CTC test ranges from approximately $350 , though published data shows wide variation depending on institutional delivery and insurance status. One major academic medical center reports a net charge of $2,689 per test (including $451 for professional interpretation) when billed to insurance . The actual cost to the facility performing the test, list price to hospitals, and patient out-of-pocket expenses differ significantly based on test volume, payer mix, and local Medicare contractor determinations. This article captures publicly available pricing; MedSource will update estimates as institutional quote data accumulates.

What the typical range is

Published pricing data for CELLSEARCH® testing sits in a wide band:

• Professional list/charge price: $2,689–$3,200 per test (including professional interpretation)
• Insurance claim reimbursement: Highly variable by payer and region; Medicare contractors use gap-fill methodology on CPT code 86152 (cell enumeration)
• Patient out-of-pocket (uninsured): May qualify for 60% institutional discounts, reducing effective cost to ~$1,000–$1,200
• Historical reported cost: $350 reported as a covered amount under some private insurance plans

The wide range reflects two realities: (1) CMS established a national payment rate only for the professional interpretation code (86153); each Medicare contractor sets its own reimbursement rate for the test code (86152) based on gap-fill methodology , and (2) private insurers cover CTC testing inconsistently. CTC testing is not a covered service for most insurance plans.

What pushes price up — features, certifications, support tier

FDA 510(k) Clearance Status

CELLSEARCH is the only CTC test cleared through the FDA 510(k) review process for metastatic breast, colorectal, and prostate cancer. This regulatory exclusivity supports premium pricing; competing platforms (RareCyte, OncoDiscover) lack equivalent FDA clearance and charge differently based on LDT (Laboratory Developed Test) regulation rather than Class II device pathways.

Complete Platform Requirement

The kit components include a preloaded reagent tray, ferrofluid-based capture reagent, immunofluorescent reagents for 16 complete tests, and specially designed cartridges . Hospitals cannot run CELLSEARCH® without the CELLTRACKS® AUTOPREP® System and CELLTRACKS ANALYZER II® System, bundling capital equipment cost into the per-test cost structure.

Technical Specifications

The system detects and enumerates circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+) from a 7.5-mL blood sample with high sensitivity and specificity . This multi-marker immunofluorescence approach is proprietary and requires manufacturer-supplied reagents, limiting generic or interchangeable alternatives.

Clinical Evidence Base

The presence of CTCs detected by CELLSEARCH® is associated with decreased progression-free survival and overall survival in patients with metastatic breast, colorectal, or prostate cancer , supporting reimbursement and institutional adoption. Published clinical validation increases perceived value and supports pricing leverage with payers.

What pushes price down — refurbished, older generation, lease, GPO contracts

Volume & GPO Agreements
Health systems and hospital networks with high CTC testing volume (>10 tests/month) may negotiate volume discounts directly with the manufacturer (now Menarini Silicon Biosystems; formerly Janssen Diagnostics). Group Purchasing Organization (GPO) contracts are not publicly listed but likely provide 10–20% reductions for large hospital systems.

Instrument Leasing
Rather than capital purchase of CELLTRACKS® AUTOPREP® and ANALYZER II® systems ($50k–$150k estimated, not confirmed), some labs lease the platform on reagent-pull agreements. Pricing shifts from one-time equipment cost to per-kit fees, reducing upfront burden but locking in consumable costs over the lease term.

Batch Testing & Carrier Systems
Laboratories using sample carriers (CellSave Preservative Tubes) to batch multiple samples reduce per-test handling overhead. Approximately 10 mL of blood is drawn into a CellSave Preservative Tube per standard specifications, and testing analyzes 7.5 mL of whole blood . Consolidated regional reference labs operating high-throughput CTC workflows achieve lower unit economics than point-of-care hospital labs.

Older Platform Generation
CELLSEARCH® has been on the market since FDA 510(k) clearance in the mid-2000s. Earlier iterations or "legacy" CELLTRACKS ANALYZER systems may be available on used laboratory equipment markets at 30–50% reductions, though manufacturers recommend current-generation instruments for optimal performance.

Hidden costs — install, training, calibration, consumables, service contracts

Instrument Installation & Qualification
Initial setup of CELLTRACKS® AUTOPREP® and ANALYZER II® systems includes site preparation, electrical/data integration, and performance qualification (PQ). Typical installed cost: $10k–$20k (not confirmed; varies by site complexity).

Staff Training & Competency
Operators require certification on immunofluorescence microscopy, system software, and QC procedures. Training typically costs $3k–$8k per technician (estimated). For labs running <5 tests/month, per-test training cost can be significant.

Quality Control & Calibration

CELLSEARCH® kits must be used with the CELLSEARCH® Circulating Tumor Cell Control Kit . Control kits are consumable and required for each assay batch, adding ~$200–$400 per kit (estimated) to the running cost.

Annual Service Contracts
Preventative maintenance, system calibration, and technical support agreements typically run $8k–$15k/year depending on platform configuration and manufacturer terms (not publicly listed).

Specimen Transport & Stability

CellSave Preservative Tubes are required for sample collection and preservation . These specialized tubes cost ~$15–$25 per unit when procured through the manufacturer. For remote labs, 2–3 day turnaround logistics may incur specimen courier charges.

Software & Compliance Updates
System software updates, CLIA/CAP compliance monitoring, and data management systems add $3k–$5k annually (estimated).

How to negotiate — concrete tactics

Request Institutional Volume Agreements
If your health system or network anticipates >20 tests/month, approach Menarini Silicon Biosystems directly (not through distributors) with a volume commitment. Specify a 3-year rolling forecast. Written forecasts often unlock 15–25% list-price reductions.

Clarify Reimbursement Floor
Before committing to in-house CELLSEARCH® capability, contact your top 3–5 insurance carriers (by covered lives) and obtain written reimbursement rates for CPT codes 86152 and 86153. Document whether each plan requires prior authorization. If <50% of anticipated patient volume is covered, consider send-out reference lab partnerships instead of capital investment.

Evaluate Send-Out vs. In-House Economics
Compare cost-per-test for outsourcing to a high-volume reference lab (e.g., Menarini's clinical lab in Pennsylvania or other CAP/CLIA-accredited centers) against in-house platform. Factor in technician FTE, overhead allocation, and instrument utilization. For <10 tests/month, send-out is typically $200–$600 cheaper per test due to reference lab economies of scale.

Bundle Instrument & Reagent Pricing
Negotiate a single price per kit inclusive of instrument maintenance and technical support rather than line-item pricing. This simplifies budget forecasting and may reveal savings through consolidated service terms.

Leverage Competitive Platforms in Discussions
RareCyte and other emerging CTC platforms may carry lower per-test costs. Mention competitive alternatives in payer communications to emphasize value justification; however, CELLSEARCH's FDA status and clinical validation provide negotiating strength for reimbursement advocacy.

When the price feels off — red flags

CPT Code 86152 Reimbursement Below $150

Medicare contractors use gap-fill methodology to set local payment rates . If a Medicare contractor's allowable for 86152 is <$150, your facility is likely below cost-recovery on reagent and labor. Request a rate adjustment or switch to reference lab send-out.

Reagent Supply Constraints or Price Spikes
CELLSEARCH® kits are manufacturer-exclusive; no generic suppliers exist. If pricing increases >15% year-over-year without notification or published justification, it may signal supply chain pressure or margin adjustment. Request a multi-year pricing lock-in clause in new contracts.

"Lease-Only" Terms Without Price Transparency
Manufacturers sometimes structure leases to obscure per-test cost through bundled fees. Demand itemized per-kit pricing and total cost of ownership (TCO) breakdowns over 5 years. If the manufacturer refuses, assume pricing flexibility is poor.

Low Specimen Volume Justification
If your lab is quoted $3,000+ per test but running <5 tests/month, the fixed overhead allocation is inflated. Consolidate testing with a nearby hospital system or reference lab to achieve volume economies.

Insurance Pre-Auth Denials at >20% Submission Rate
If >20% of your CELLSEARCH® orders are denied at pre-authorization despite medical necessity, the test may not be recognized as standard-of-care by regional payers. Confirm local coverage policies (LCD) on CMS database before building inventory.

Sources

Michigan Medicine Laboratories CTC Patient Billing Guidelines (2022)

Cancer Today Magazine: "A Blood Test for Cancer: Liquid Biopsies" (2016)

Veridex/Janssen Diagnostics CPT Code Announcement (2012) — FDA 510(k) clearance; CPT codes 86152, 86153

CELLSEARCH® product kit specification sheet — ferrofluid reagent, 16-test cartridges, control kit requirements

CELLSEARCH® clinical trial methodology documentation — CellSave tube specifications and blood volume

• Menarini Silicon Biosystems, Inc., official website (reimbursement, clinical lab certification: CAP/CLIA/ISO 15189)

---

Note: This estimate reflects publicly available pricing from institutional charge masters, payer reimbursement ranges, and clinical literature as of May 2026. MedSource does not currently maintain proprietary institutional contract pricing. Rates vary significantly by region, payer, and test volume. Always confirm local reimbursement and negotiate based on your institution's specific utilization and payer mix.